Welcome to our dedicated page for CRTX news (Ticker: CRTX), a resource for investors and traders seeking the latest updates and insights on CRTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRTX's position in the market.
Cortexyme (Nasdaq: CRTX) announced new preclinical data on atuzaginstat (COR388) for periodontal disease, validated during the IADR 2021 conference. This data highlights its effectiveness in engaging and inhibiting P. gingivalis within biofilms, a challenge for traditional antibiotics. The second-generation inhibitor COR588 also showed similar results and is set to enter Phase I trials. The ongoing pivotal GAIN Trial for Alzheimer’s, with top-line data expected in Q4 2021, includes a 233-patient sub-study evaluating periodontal disease endpoints.
Cortexyme, Inc. (Nasdaq: CRTX) is advancing a pivotal trial in Alzheimer’s disease, with top-line data expected in Q4 2021. The company will host a symposium at the Alzheimer’s Association International Conference® 2021 on July 27, focusing on innovative disease-modifying treatments. Cortexyme's lead candidate, atuzaginstat (COR388), targets the pathogen P. gingivalis, found in 90% of Alzheimer’s patients. The GAIN Trial includes 643 participants and aims to demonstrate the drug's efficacy. For more info, visit www.cortexyme.com.
Cortexyme, Inc. (Nasdaq: CRTX) is hosting a webinar series to discuss its lead drug candidate, atuzaginstat (COR388), a lysine-gingipain inhibitor targeting Alzheimer’s and periodontal diseases. The series occurs in two parts on July 23 and July 30, 2021, coinciding with major scientific conferences. KOLs will present findings on the links between P. gingivalis and neurodegeneration. Top-line data from the pivotal GAIN Trial and the REPAIR study is expected in Q4 2021, with updates provided during the sessions.
Cortexyme, Inc. (Nasdaq: CRTX) presented updated demographic and biomarker data at the ASCP 2021 Annual Meeting related to its GAIN study for Alzheimer's disease treatment. Key findings showed that 84% of participants had Aβ positivity, while 88% displayed total Tau levels consistent with Alzheimer's. Notably, 64% carried the ApoE4 gene. The ongoing Phase 2/3 trial involves 643 subjects assessing atuzaginstat's efficacy in inhibiting P. gingivalis-related neurodegeneration, with top-line data expected in Q4 2021.
Cortexyme, Inc. (Nasdaq: CRTX) is advancing a pivotal trial for Alzheimer's disease with top-line data expected in Q4 2021. The COO and CFO, Chris Lowe, will participate in two virtual investor conferences in June 2021: the Jefferies Healthcare Conference on June 2 at 2:00 p.m. EDT and the JMP Securities Life Sciences Conference on June 16 at 3:00 p.m. EDT. Webcasts of these events will be available on Cortexyme's Investor Calendar for 90 days. Cortexyme's innovative therapies target Alzheimer's and other degenerative diseases, focusing on the infectious pathogen P. gingivalis.
Cortexyme, Inc. (Nasdaq: CRTX) provided updates on clinical data and first quarter 2021 financial results, emphasizing progress in its pivotal GAIN Trial. The company expects top-line data in Q4 2021 for Alzheimer’s and periodontal disease indications. Financially, Cortexyme reported a net loss of $23.1 million for Q1 2021 and maintained a cash position of $170.8 million, sufficient to fund operations through 2023. Key milestones include successful pharmacological studies for its lead candidate atuzaginstat and ongoing research supporting its role in Alzheimer’s disease.
Cortexyme, Inc. (Nasdaq: CRTX) is progressing with a pivotal trial for Alzheimer’s disease, with topline data expected in Q4 2021. Chris Lowe, the COO and CFO, is scheduled to participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on May 11, 2021, at 3:30 p.m. EDT. This event will be accessible via the Investor Calendar on Cortexyme’s website and archived for 90 days. Cortexyme focuses on innovative therapeutics targeting neurodegenerative diseases, specifically advancing its candidate, atuzaginstat (COR388), through the ongoing GAIN Trial.
Cortexyme, Inc. (Nasdaq: CRTX) announced that CEO Casey Lynch will participate in a virtual fireside chat at the Stifel 3rd Annual CNS Day on April 1, 2021, at 10:00 a.m. EDT. This event coincides with the company's ongoing Phase 2/3 GAIN Trial for its lead therapeutic candidate, atuzaginstat, aimed at treating Alzheimer’s disease. Topline data from the trial is expected in Q4 2021. The webcast will be available on the Cortexyme investor site and archived for 90 days.
Cortexyme, Inc. (Nasdaq: CRTX) announced that Chris Lowe, COO and CFO, will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 4:00 p.m. EDT. This virtual event will include a live webcast available on Cortexyme's Investor Calendar page, where it will remain accessible for 90 days. Cortexyme is focused on developing treatments for Alzheimer’s and other degenerative diseases, with its lead candidate, atuzaginstat (COR388), currently in the GAIN Trial, a Phase 2/3 study targeting a specific pathogen associated with degeneration.
Cortexyme, Inc. (Nasdaq: CRTX) has partnered with the Parkinson Study Group (PSG) to create an Advisory Board aimed at enhancing its Parkinson’s disease research. The collaboration will leverage PSG's expertise to explore the impact of Porphyromonas gingivalis on Parkinson's disease. Additionally, Cortexyme will present new findings at the AD/PD 2021 conference that reinforce the link between P. gingivalis and neurodegeneration in Alzheimer's disease. The ongoing GAIN Trial for atuzaginstat (COR388) continues as Cortexyme advances its therapeutic candidate in clinical stages.
FAQ
What is the market cap of CRTX (CRTX)?
